Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
| Status: | Archived |
|---|---|
| Conditions: | Lung Cancer, Ovarian Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | November 2010 |
| End Date: | July 2011 |
A Phase I Study of Intravenous (IV) Palifosfamide-tris Administered in Combination With IV Etoposide and IV Carboplatin in Patients With Malignancies for Which Etoposide and Carboplatin Are an Appropriate Choice
This an an open-label study to define the safety profile and the maximum tolerated dose and
confirm the clinical effective dose of palifosfamide-tris given intravenously in combination
with etoposide and carboplatin in a wide range of cancers which etoposide and carboplatin
are normally given. Once the maximum dose of palifosfamide-tris is determined,a Phase II
study using the 3 agents combined will begin.
We found this trial at
4
sites
Washington University Washington University creates an environment to encourage and support an ethos of wide-ranging...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials